Celsion Shares Outstanding 2006-2021 | CLSN

Celsion shares outstanding from 2006 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Celsion Annual Shares Outstanding
(Millions of Shares)
2020 32
2019 22
2018 18
2017 8
2016 2
2015 2
2014 1
2013 1
2012 1
2011 0
2010 0
2009 0
2008 0
2007 0
2006 0
2005 0
Celsion Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 86
2021-03-31 66
2020-12-31 32
2020-09-30 34
2020-06-30 30
2020-03-31 26
2019-12-31 22
2019-09-30 22
2019-06-30 21
2019-03-31 19
2018-12-31 18
2018-09-30 18
2018-06-30 18
2018-03-31 18
2017-12-31 8
2017-09-30 8
2017-06-30 7
2017-03-31 2
2016-12-31 2
2016-09-30 2
2016-06-30 2
2016-03-31 2
2015-12-31 2
2015-09-30 2
2015-06-30 1
2015-03-31 1
2014-12-31 1
2014-09-30 1
2014-06-30 1
2014-03-31 1
2013-12-31 1
2013-09-30 1
2013-06-30 1
2013-03-31 1
2012-12-31 1
2012-09-30 1
2012-06-30 1
2012-03-31 1
2011-12-31 0
2011-09-30 0
2011-06-30 0
2011-03-31 0
2010-12-31 0
2010-09-30 0
2010-06-30 0
2010-03-31 0
2009-12-31 0
2009-09-30 0
2009-06-30 0
2009-03-31 0
2008-12-31 0
2008-09-30 0
2008-06-30 0
2008-03-31 0
2007-12-31 0
2007-09-30 0
2007-06-30 0
2007-03-31 0
2006-12-31 0
2006-09-30 0
2006-06-30 0
2006-03-31 0
2005-12-31 0
2005-09-30 0
2005-06-30 0
2005-03-31 0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.083B $0.001B
Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Long Island Jewish Health System.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $128.460B 8.55
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $8.952B 0.00
Emergent Biosolutions (EBS) United States $2.717B 6.55
Arcus Biosciences (RCUS) United States $2.502B 0.00
Myovant Sciences (MYOV) United Kingdom $1.906B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.820B 0.00
Zymeworks (ZYME) Canada $1.088B 0.00
Ambrx Biopharma (AMAM) United States $0.513B 0.00
SQZ Biotechnologies (SQZ) United States $0.343B 0.00
Enzo Biochem (ENZ) United States $0.159B 15.57